Ashurst is advising Evercore Partners, J.P. Morgan and Nomura in relation to Takeda Pharmaceutical Company’s £46 billion recommended offer for Shire, announced today.

The acquisition is expected to create a leading global biopharmaceutical company incorporated and headquartered in Japan, with strong inherited values, driven by innovative and world-class R&D and the scale to drive future development.  Under the terms of the acquisition, shareholders in Shire will be entitled to receive $30.33 in cash and either 0.839 new Takeda Shares or 1.678 Takeda ADSs for each share they hold. These terms value the entire issued and to be issued ordinary share capital of Shire at approximately £46 billion.

Evercore Partners, J.P. Morgan and Nomura are acting as joint financial advisers to Takeda in connection with the acquisition.

The Ashurst team is being led by partners Robert Ogilvy Watson (corporate), Tom Mercer (corporate) and Tim Rennie (banking), assisted by senior associate Briony Holcombe (finance) and solicitor James Powell (corporate).